Research programme: cancer therapeutics - NovelixAlternative Names: NVX-144; NVX-188
Latest Information Update: 04 Sep 2009
At a glance
- Originator University of Southern California
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Integrin alphaVbeta3 antagonists; Interleukin 24 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Sep 2009 Preclinical development is ongoing in USA
- 19 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)